Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00127478 · ClinicalTrials.gov registry record · Phase 2
A Long Term Safety Study With Atrasentan
A Phase 2 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 2
- Development phase
- 166
- Enrollment target
NCT00127478: Completed Phase 2 study, sponsored by Abbott.
NCT00127478 is a Phase 2 study that has completed, run by Abbott. The registered enrollment target is 166 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00127478, a Phase 2 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 166 participants
- Enrollment target
Study Summary
The primary purpose of the study is to evaluate long-term safety and tolerability of atrasentan 10 mg in men with hormone refractory prostate cancer.
Interventions
- DRUG Atrasentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2001-07 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
What the finished NCT00127478 record still lists
NCT00127478 is an interventional study that assigns participants to a tested intervention. The registered 166 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% higher).
The record links to 0 conditions, and to 1 intervention - of which Atrasentan is the first listed.
NCT00127478 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00127478 about?
NCT00127478 is a clinical study titled "A Long Term Safety Study With Atrasentan". The primary purpose of the study is to evaluate long-term safety and tolerability of atrasentan 10 mg in men with hormone refractory prostate cancer.
What is the current status of trial NCT00127478?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 166 participants. The study started on 2001-07. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00127478?
The interventions under investigation include: Atrasentan (DRUG).
Who is sponsoring clinical trial NCT00127478?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00127478's enrollment target sits among peer trials
166 406th of 2000 higher than 1,591 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747303 · 166 participants · Phase 2
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
- NCT03806283 · 166 participants
Mechanisms of Pregnancy Vascular Adaptations
- NCT04040452 · 166 participants · Phase 4
Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery
- NCT04375813 · 166 participants · Phase 2
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia